GBC Blog

Curetis Global Installed Base Expanding

Curetis’ Global Installed Base Expanding to Over 150 Unyvero Analyzers – Completion of EMEA Direct Sales team build-out drives 46% growth in system installations over the course of 2016 – Reported unaudited FY 2016 revenue and strong year-end cash position Amsterdam, the Netherlands, and Holzgerlingen, Germany, January 31, 2017 – Curetis N.V. (Euronext: CURE, the…

Read More

Journal of “Cancer Treatment and Research Communications” Publishes Results of Study with Blood Test Epi proColon®

Journal of “Cancer Treatment and Research Communications” Publishes Results of Study with Blood Test Epi proColon® ADMIT Study Results Demonstrate Higher Uptake of a Colorectal Cancer Screening Blood Test Compared to a Fecal Test 11.01.2017 Berlin (Germany) and Germantown, MD (U.S.A.), January 11, 2017 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), announced that…

Read More

ARUP Offers Epi proColon Blood Test

ARUP Laboratories to Offer Epi proColon®, Epigenomics’ Blood-Based Colorectal Cancer Screening Test (Press Release) Berlin (Germany) and Germantown, MD (U.S.A.), November 8, 2016 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), announced that ARUP Laboratories (Salt Lake City, Utah) is the next major U.S. laboratory to offer Epi proColon®, the first and only FDA-approved…

Read More

Epigenomics AG JAMA Letter to Editor

USPSTF Guidelines May Have Used Old Data on Epigenomics Colorectal Cancer Screening Test Oct 26, 2016 NEW YORK (GenomeWeb) – The US Preventive Services Task Force (USPSTF) failed to take into account the most recent data available on Epigenomics’ Epi proColon colorectal cancer screening test when warning about its relatively low efficacy in recently updated…

Read More

CRC Detection Legislation

New Legislation Would Require CMS Coverage for Blood-Based Colorectal Cancer Screens Sep 29, 2016 | GenomeWeb [Original Article] NEW YORK – A bipartisan group of Congressional representatives today unveiled a bill that would require Medicare coverage for qualifying US Food and Drug Administration-approved blood-based colorectal cancer screening tests in order to boost screening in traditionally…

Read More

Saliva Test for Cancer

Color Genomics Raises $45M in Series B. With a little Help from Bono 28 SEP 2016 – Liz Harley [Original Article] Yep, you read that correctly. Maybe the U2 front man has finally found what he’s looking for (sorry) by investing in cancer testing startup Color Genomics. The company has announced a series B investment round…

Read More

EUA for Zika Test

Vela Diagnostics Gets Emergency U.S. Authorization for Zika Test HEALTH NEWS | Mon Sep 26, 2016 [Original Post] Vela Diagnostics said its test for the Zika virus had received “emergency use authorization” from the U.S. Food and Drug Administration. The test, already approved in Europe, is validated for plasma, serum and urine samples, the Singapore-based…

Read More

IVD Market to Reach $81B by 2022

In Vitro Diagnostic Market is Expected to Reach $81.3 Billion, Globally, by 2022 – Allied Market Research Aug 31, 2016 PORTLAND, Oregon, August 31, 2016 /PRNewswire/ Original Article According to a new report published by Allied Market Research, titled, “World In Vitro Diagnostics (IVD) Market”, the world in vitro diagnostics (IVD) market is estimated to…

Read More